Chromium picolinate balances the metabolic and clinical markers in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled trial
F Kooshki, F Moradi, A Karimi, HR Niazkar… - European Journal of …, 2021 - journals.lww.com
Objective Nonalcoholic fatty liver disease (NAFLD) is a complicated disease and is
considered as a severe global health problem affecting 30% of adults worldwide. The
present study aimed to evaluate changes in oxidative stress, adipokines, liver enzyme, and
body composition following treatment with chromium picolinate (CrPic) among patients with
NAFLD.
considered as a severe global health problem affecting 30% of adults worldwide. The
present study aimed to evaluate changes in oxidative stress, adipokines, liver enzyme, and
body composition following treatment with chromium picolinate (CrPic) among patients with
NAFLD.
以上显示的是最相近的搜索结果。 查看全部搜索结果